Discovery Portfolio
- M. tuberculosis Protein Kinase Inhibitors Several chemical scaffolds with various PknA, PknB and PknG selectivity profiles Vertex Pharmaceuticals, Incorporated
- Fungal metabolites Mycosynthetix, University of Illinois at Chicago
- Actinomycete metabolites cyclic peptide University of Illinois at Chicago, Myongji University
- Phenotypic hit to lead Multiple novel structural classes Lilly TB Drug Discovery Initiative
- Novel hit-lead programs Novel structural class Lilly TB Drug Discovery Initative
- Whole-Cell Hit-to-Lead Novel structural classes AstraZeneca R&D Bangalore, TB Alliance
- Indigoids University of Illinois at Chicago
- Whole-Cell Hit-to-Lead GlaxoSmithKline, TB Alliance
- Malate Synthase Inhibitors Texas A&M University
- Menaquinone Synthase Inhibitors Colorado State University
- Inhibitors of Mycobacterium Tuberculosis Energy Metabolism Various Classes UPenn,TB Alliance
- Inhibitors of isoprenoid biosynthesis Lilly TB Drug Discovery Initiative
- ATP Synthesis Inhibitors TB Alliance, Calibr
- Diarylquinolines Diarylquinoline TB Alliance, University of Auckland, Janssen
- Riminophenazines Riminophenazines antibiotic TB Alliance, Institute of Materia Medica, The Beijing Tuberculosis and Thoracic Tumor Research Institute and University of Illinois
- InhA Inhibitors Novel structural class GlaxoSmithKline
- LeuRS inhibitors Oxaboroles Anacor Pharmaceuticals, GlaxoSmithKline
- Mycobacterial Gyrase Inhibitors Novel structural class TB Alliance, GlaxoSmithKline
- Pyrazinamide Analogs Pyrazinamide/nicotinamide analogs TB Alliance/Yonsei University
- TL1 Inhibitors Capuramycins Sequella
- SCAR - Ruthenium (II) phosphine/diimine/picolinate complexes: Inorganic compounds as agents against tuberculosis Inorganic Compounds FAPESP/Brazil
- Spectinamides Spectinomycin analogs St Jude Children's Research Hospital, University of Tennessee Health Science Center, Colorado State University, University of Zurich, Microbiotix
- DprE Inhibitors TB Alliance, Calibr